StreetInsider.com News Articles

Form SCHEDULE 13G/A Biodexa Pharmaceuticals Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501959.html

Form SCHEDULE 13G/A Biodexa Pharmaceuticals Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501959.html

Form 6-K Biodexa Pharmaceuticals For: May 14

Thu, 14 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260514/26494282.html

Form 6-K Biodexa Pharmaceuticals For: May 14

Thu, 14 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260514/26494282.html

Biodexa proposes share capital reorganization at annual meeting

Thu, 14 May 2026 08:31:20 -0400

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) announced proposals to reorganize its share capital structure at the company's annual general meeting scheduled for June 17, 2026.

The clinical-stage biopharmaceutical company currently has 373,056,808,922 ordinary shares outstanding with a nominal value of £0.000001 each. Based on the existing ordinary share to American Depositary Share ratio of 500,000:1, this represents approximately 746,113 ADSs outstanding.

Under the proposed reorganization, the company would implement a reverse stock split consolidating every 10,000 existing ordinary shares into one ordinary share with a nominal value of £0.01. This would reduce the number of ordinary shares to approximately 37.3 million.

Each consolidated ordinary

Biodexa issues letter to Shareholders

Thu, 14 May 2026 08:30:00 -0400

May 14, 2026

Biodexa issues letter to Shareholders

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company’s share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder’s rights.

“Dear Shareholder,

Annual General Meeting

Proposals to Reorganize Share Capital Without Affecting Shareholder’s Rights or Number of

Biodexa issues letter to Shareholders

Thu, 14 May 2026 08:30:00 -0400

May 14, 2026

Biodexa issues letter to Shareholders

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company’s share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder’s rights.

“Dear Shareholder,

Annual General Meeting

Proposals to Reorganize Share Capital Without Affecting Shareholder’s Rights or Number of

Biodexa issues letter to Shareholders

Thu, 14 May 2026 08:30:00 -0400

May 14, 2026

Biodexa issues letter to Shareholders

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company’s share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder’s rights.

“Dear Shareholder,

Annual General Meeting

Proposals to Reorganize Share Capital Without Affecting Shareholder’s Rights or Number of

Biodexa issues letter to Shareholders

Thu, 14 May 2026 08:30:00 -0400

May 14, 2026

Biodexa issues letter to Shareholders

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company’s share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder’s rights.

“Dear Shareholder,

Annual General Meeting

Proposals to Reorganize Share Capital Without Affecting Shareholder’s Rights or Number of

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260402/26267390.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260402/26267390.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260402/26267391.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260402/26267391.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260402/26267392.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260402/26267392.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260402/26267393.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260402/26267393.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260402/26267385.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260402/26267385.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260402/26267386.html

Form 424B3 Biodexa Pharmaceuticals

Thu, 02 Apr 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260402/26267386.html

Biodexa partners with Syngene to manufacture MTX240 clinical supplies

Thu, 02 Apr 2026 08:31:55 -0400

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) announced a partnership with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) to manufacture both the active pharmaceutical ingredient and dosage form for MTX240, according to a company statement.
MTX240 is being developed as a treatment for gastrointestinal stromal tumors (GIST). The drug operates as a molecular glue that brings two intracellular proteins, PDE3a and SLFN12, into proximity to form a stable complex, which enables cell death through a mechanism independent of KIT signaling.
Dan Palmer, Vice President of Technology at Biodexa, said the partnership marks the second collaboration between the companies. "Syngene manufactured tolimidone dosage form for

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Thu, 02 Apr 2026 08:30:00 -0400

April 2, 2026

Biodexa Announces Partnership with Syngene
To Manufacture MTX240 GMP Clinical Trial Supplies

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) (“Syngene”) for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.

Commenting, Dan Palmer, Vice President, Technology at Biodexa said “We are delighted to be partnering with Syngene for

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Thu, 02 Apr 2026 08:30:00 -0400

April 2, 2026

Biodexa Announces Partnership with Syngene
To Manufacture MTX240 GMP Clinical Trial Supplies

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) (“Syngene”) for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.

Commenting, Dan Palmer, Vice President, Technology at Biodexa said “We are delighted to be partnering with Syngene for

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Thu, 02 Apr 2026 08:30:00 -0400

April 2, 2026

Biodexa Announces Partnership with Syngene
To Manufacture MTX240 GMP Clinical Trial Supplies

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) (“Syngene”) for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.

Commenting, Dan Palmer, Vice President, Technology at Biodexa said “We are delighted to be partnering with Syngene for